Top

Published in:

01-03-2020 | Cholangiocarcinoma | Research Article

Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21

Published in: Clinical and Translational Oncology | Issue 3/2020

Abstract

Background

Intrahepatic cholangiocarcinoma (ICC) is one of the most devastating cancers of the gastrointestinal tract. It is crucial to determine the accurate prognostic factors and find new therapeutic strategies. Meanwhile, O⁶-methylguanine–DNA methyltransferase (MGMT) is associated with malignant tumor progression. Thus, further studies are needed to investigate whether MGMT plays a similar role in ICC.

Materials and methods

Quantitative real-time PCR, western blot, and immunohistochemistry staining were used to detect the expression of MGMT in ICC tissues. The correlations between MGMT expression and clinicopathologic features were analyzed. The cell-proliferation assay and colony-formation assay were applied to evaluate proliferation ability, while methylation-specific PCR were used to detect the methylation status of the MGMT promoter CpG island in ICC tissues and cells.

Results

Our study found that the expression of MGMT was decreased in ICC tissues when compared with paired normal tissues. In addition, we demonstrated that MGMT expression was positively correlated with overall survival rates and tumor histological grade. Silencing of MGMT significantly promoted cell proliferation in ICC. Further research showed that silencing of MGMT induced cells to enter S phase by inhibiting p21, p27, and Cyclin E expression, ultimately promoting ICC proliferation. We also demonstrated that the MGMT promoter was highly methylated in ICC, and the levels of MGMT and p21 mRNA increased after DNA demethylation. In addition, the levels of MGMT and p21 protein were positively correlated in ICC tissues.

Conclusion

MGMT may play a critical role in carcinogenesis and the development of ICC, and provides a new marker of clinical prognosis and target for ICC treatment.

Available only for authorised users

Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):35–433. https://doi.org/10.21037/hbsn.2016.10.02.CrossRefPubMedPubMedCentral

Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22–34. https://doi.org/10.21037/hbsn.2016.11.04.CrossRefPubMedPubMedCentral

Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, et al. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxford). 2015;17(12):1119–23. https://doi.org/10.1111/hpb.12504.CrossRefPubMedPubMedCentral

Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48(6):816–20.CrossRef

Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50(19):6119–29.PubMed

Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control. 2011;22(2):301–9. https://doi.org/10.1007/s10552-010-9698-z.CrossRefPubMed

Nagy E, Gajjar KB, Patel II, Taylor S, Martin-Hirsch PL, Stringfellow HF, et al. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br J Cancer. 2014;110(12):2874–80. https://doi.org/10.1038/bjc.2014.263.CrossRefPubMedPubMedCentral

Chen GD, Qian DY, Li ZG, Fan GY, You KL, Wu YL. Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells. Cell Biochem Funct. 2017;35(8):488–96. https://doi.org/10.1002/cbf.3282.CrossRefPubMed

Wang K, Chen D, Qian Z, Cui D, Gao L, Lou M. Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. Cancer Cell Int. 2017;17:117. https://doi.org/10.1186/s12935-017-0491-x.CrossRefPubMedPubMedCentral

10.

Mostofa A, Punganuru SR, Madala HR, Srivenugopal KS. S-phase specific downregulation of human O(6)-methylguanine DNA methyltransferase (MGMT) and its serendipitous interactions with PCNA and p21(cip1) proteins in glioma cells. Neoplasia. 2018;20(4):305–23. https://doi.org/10.1016/j.neo.2018.01.010.CrossRefPubMedPubMedCentral

11.

Banan R, Christians A, Bartels S, Lehmann U, Hartmann C. Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun. 2017;5(1):98. https://doi.org/10.1186/s40478-017-0500-2.CrossRefPubMedPubMedCentral

12.

Sobieszkoda D, Czech J, Gablo N, Kopanska M, Tabarkiewicz J, Kolacinska A, et al. MGMT promoter methylation as a potential prognostic marker for acute leukemia. Arch Med Sci. 2017;13(6):1433–41. https://doi.org/10.5114/aoms.2017.71067.CrossRefPubMedPubMedCentral

13.

Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, et al. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer. 2017;116(10):1279–86. https://doi.org/10.1038/bjc.2017.109.CrossRefPubMedPubMedCentral

14.

Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79. https://doi.org/10.1016/S0140-6736(13)61903-0.CrossRefPubMedPubMedCentral

15.

Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis. 2014;34(4):456–64. https://doi.org/10.1055/s-0034-1394144.CrossRefPubMedPubMedCentral

16.

Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296–307. https://doi.org/10.1038/nrc1319.CrossRefPubMed

17.

Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23. https://doi.org/10.1038/nature03097.CrossRefPubMed

18.

el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–25.CrossRef

19.

Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366(6456):701–4. https://doi.org/10.1038/366701a0.CrossRefPubMed

20.

Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55(22):5187–90.PubMed

21.

Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, et al. Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival. Clin Epigenetics. 2015;7:110. https://doi.org/10.1186/s13148-015-0145-6.CrossRefPubMedPubMedCentral

22.

Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 2005;18(3):412–20. https://doi.org/10.1038/modpathol.3800287.CrossRefPubMed

Title: Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21
Publication date: 01-03-2020
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: Clinical and Translational Oncology / Issue 3/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02140-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma

The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis

Predictive factors for persistent and late radiation complications in breast cancer survivors

Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer

Circulating tumor cells in the clinical cancer diagnosis

De-escalation treatment of axilla in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer